as a whole.
Aktuellt
SENASTE
Following Alligator’s Q2 results announcements, we make minor estimate revisions and reiterate our valuation range of SEK 15-19 per share. While the Q2 numbers were largely in line with our expectations, we like Alligator’s statement that recruitment to ongoing clinical phase I studies has resumed and that it currently sees no impact from COVID-19 on study completion times
as a whole.
LÄS MER
